Portola Pharmaceuticals Inc. (PTLA)

25.99
0.09 0.35
NASDAQ : Health Technology
Prev Close 26.08
Open 26.11
Day Low/High 25.66 / 26.12
52 Wk Low/High 14.81 / 42.17
Volume 70.38K
Avg Volume 992.50K
Exchange NASDAQ
Shares Outstanding 68.11M
Market Cap 1.78B
EPS -5.30
P/E Ratio N/A
Div & Yield N.A. (N.A)
Cramer: Don't Risk It All on a Small Biotech Unless You're Willing to Lose It All

Cramer: Don't Risk It All on a Small Biotech Unless You're Willing to Lose It All

Without at least one approved drug, I am tempted to say you should just take a pass.

Don't Let Stock Picking Scare You: Cramer's 'Mad Money' Recap (Wednesday 7/19/17)

Don't Let Stock Picking Scare You: Cramer's 'Mad Money' Recap (Wednesday 7/19/17)

Jim Cramer says do your homework, be informed and don't let the wise guys trip you up with their warnings about 'single-stock risk.'

Short Interest In Portola Pharmaceuticals Drops 26.2%

Short Interest In Portola Pharmaceuticals Drops 26.2%

The most recent short interest data has been released for the 06/30/2017 settlement date, which shows a 1,410,701 share decrease in total short interest for Portola Pharmaceuticals, Inc. , to 3,978,700, a decrease of 26.18% since 06/15/2017.

NovoCure, NextEra, O'Reilly: 'Mad Money' Lightning Round (7/7/17)

NovoCure, NextEra, O'Reilly: 'Mad Money' Lightning Round (7/7/17)

A look at Jim Cramer's thoughts on stocks of interest to "Mad Money" viewers.

What to Watch During the Week: Cramer's 'Mad Money' Recap (Friday 7/7/17)

What to Watch During the Week: Cramer's 'Mad Money' Recap (Friday 7/7/17)

Earnings and Fed speakers are on tap in the next few days.

These 3 Small Biotechs Have a Healthy Shot

These 3 Small Biotechs Have a Healthy Shot

Several firms hiked price targets on Portola into the $70s this week.

Give These 3 Small Biotechs a Shot

Give These 3 Small Biotechs a Shot

Several firms hiked price targets on Portola into the $70s this week.

Here Comes a Big Breakout For Alibaba

Here Comes a Big Breakout For Alibaba

What the charts say.

Portola Pharmaceuticals Presents Interim Phase 2a Safety And Efficacy Data For Cerdulatinib At The International Congress Of Malignant Lymphoma

Oral, Dual SYK/JAK Inhibitor Provides Opportunity for Differentiated Activity in B-cell and other Hematological Malignancies

The 'Gnarly 9' Biotechs Will Test the FDA's Mettle

The 'Gnarly 9' Biotechs Will Test the FDA's Mettle

The firms all have drugs they want the feds to bend the rules to approve.

Could These 9 Drugs Gain FDA Approval in the Age of Trump?

Could These 9 Drugs Gain FDA Approval in the Age of Trump?

Nine biotech and drug companies want FDA approval, but need changed standards to get it.

The 'Gnarly 9' Biotechs Will Test the FDA's Mettle

The 'Gnarly 9' Biotechs Will Test the FDA's Mettle

The firms all have drugs they want the feds to bend the rules to approve.

4 Small-Cap Biotech Stars

4 Small-Cap Biotech Stars

I'm still enthusiastic about the sector, but it is critical to also be prudent.

4 Small-Cap Biotech Stars

4 Small-Cap Biotech Stars

I'm still enthusiastic about the sector, but it is critical to also be prudent.

Analysts' Actions -- Danaher, Goldman Sachs, Goodyear, Wendy's and More

Analysts' Actions -- Danaher, Goldman Sachs, Goodyear, Wendy's and More

Here are Friday's top research calls, including upgrades for Danaher and Wendy's, and downgrades for Goldman Sachs and Goodyear Tire.

Synergy, Portola Still in My Sights

Synergy, Portola Still in My Sights

Both pharma companies are promising names that easily could become buyout targets.

TheStreet Quant Rating: D- (Sell)